Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic

[
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic
[og_img]
https://www.investing.com/news/press-releases/savara-presented-new-data-from-pivotal-phase-3-impala2-trial-of-molgramostim-inhalation-solution-molgramostim-in-patients-with-autoimmune-pulmonary-alveolar-proteinosis-apap-at-american-thoracic-93CH-4051701


Investing.com